Hongbo Lu Buys 25,985 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Hongbo Lu bought 25,985 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was acquired at an average cost of $22.50 per share, for a total transaction of $584,662.50. Following the completion of the purchase, the director directly owned 347,968 shares in the company, valued at approximately $7,829,280. This represents a 8.07% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zenas BioPharma Price Performance

Shares of ZBIO stock traded up $0.29 during trading hours on Friday, reaching $26.40. The company had a trading volume of 1,084,522 shares, compared to its average volume of 1,195,034. Zenas BioPharma, Inc. has a 12-month low of $6.11 and a 12-month high of $44.60. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -3.73 and a beta of -1.50. The stock has a fifty day moving average of $27.82 and a 200-day moving average of $25.51.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Institutional Investors Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. boosted its position in shares of Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after purchasing an additional 853,740 shares during the period. Vanguard Group Inc. lifted its stake in Zenas BioPharma by 25.0% during the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after purchasing an additional 290,307 shares in the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new position in Zenas BioPharma during the fourth quarter worth $5,950,000. Invesco Ltd. purchased a new position in shares of Zenas BioPharma during the third quarter worth $3,237,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Zenas BioPharma in the fourth quarter valued at $4,746,000.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ZBIO. Citigroup raised their price objective on shares of Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Wall Street Zen downgraded shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Morgan Stanley lowered shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $37.00 to $19.00 in a research report on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Finally, Wedbush reissued an “outperform” rating and set a $45.00 target price on shares of Zenas BioPharma in a research note on Monday, December 22nd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Zenas BioPharma has a consensus rating of “Moderate Buy” and an average target price of $43.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.